Cell & Gene Therapies in Respiratory Disorders: Therapeutic Analysis
Description
Cell & Gene Therapies in Respiratory Disorders: Therapeutic Analysis
Summary
The cell and gene therapies (CGTs) landscape for respiratory diseases is currently in the early stages of development, with no marketed CGTs to date.
Reasons to Buy
Summary
The cell and gene therapies (CGTs) landscape for respiratory diseases is currently in the early stages of development, with no marketed CGTs to date.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CGT in Respiratory market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact Respiratory disease targeting CGT therapeutics market in the future.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
41 Pages
- Global CGT Sales Are Forecast to Reach $51.6 Billion by 2030
- Report Scope
- What Is Cell & Gene Therapy?
- History of the Development of CGT in Respiratory Disorders
- Challenges and Opportunities of CGTs in Respiratory Disorders
- Regulation of CGTs in the 8MM
- Top 20 Respiratory Disorders with CGT Development
- Respiratory Disorders with the Most CGT Pipeline Assets
- Top Five Respiratory Disorders with the Most CGT Pipeline Assets
- Top Five Respiratory Indications Stratified by Molecule Type
- CGTs in Respiratory Indications - Phase II/III
- CGT Market Catalysts Are Limited to a Single Company for the Next Five Years
- Industry Trends in the Application of CGTs in Respiratory Disorders
- CGT Candidates Have Lower PTSR vs. Indication Benchmarks
- Sales Are Forecast to Reach $62 Million by 2030
- Methodology
- Methodology - Sales Forecasts
- Methodology - PTSR and LoA Analysis
- Primary Research - KOL Information
- Bibliography
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


